Sle treatment in charts, according to cmdt
Reading File
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
general-purpose
Search the medical textbook library database for SLE (systemic lupus erythematosus) treatment content from Harrison's Principles of Internal Medicine (ISBN 9781265977061), Goldman-Cecil Medicine (ISBN 9780323930345), and The Washington Manual (ISBN 9781975190620). Use query_library_db to: 1. Search headings_fts for 'lupus AND treatment' or 'SLE AND management' filtered to these books 2. Then read the relevant block files to extract ALL treatment information — drug therapies, dosing, management by disease severity/organ system, monitoring, etc. SQL to find relevant sections: ```sql SELECT title, book_title, '/textbooks/' || block_file_path AS file_path, line_number, para_line_ranges, para_count FROM headings_fts WHERE headings_fts MATCH 'lupus treatment OR lupus management OR lupus therapy' ORDER BY rank LIMIT 15 ``` Also try: ```sql SELECT book_title, section_heading, '/textbooks/' || block_file_path AS file_path, line_start, line_end, snippet(paragraphs_fts, 0, '>>>', '<<<', '...', 40) as snippet FROM paragraphs_fts WHERE paragraphs_fts MATCH '"systemic lupus" AND treatment' ORDER BY rank LIMIT 15 ``` Then read the most relevant block files (especially from Harrison's ISBN 9781265977061 or Goldman-Cecil ISBN 9780323930345) using read_file with offset and limit=100 per call, paginating through the sections on SLE treatment. Return ALL treatment content you find — drugs, doses, indications by severity, monitoring parameters, special considerations. Include the book name and approximate page/section references. Format clearly so it can be turned into treatment charts/tables.
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Finding Sources
Reading File
Reading File
Reading File
The subagent found comprehensive SLE treatment content from Harrison's 22e, Goldman-Cecil, and The Washington Manual. Note that CMDT is not in the library, but these sources cover equivalent evidence-based content. Here is the full treatment reference in chart format:
Note: CMDT is not available in the textbook library. The charts below are drawn from Harrison's Principles of Internal Medicine 22e, Goldman-Cecil Medicine, and The Washington Manual of Medical Therapeutics — all covering the same evidence-based SLE treatment guidelines.
SLE Treatment — Structured Charts
Chart 1: Disease Severity Classification & Treatment Framework
| Severity | Criteria | First-Line Treatment |
|---|---|---|
| Mild | Fatigue, arthralgia, mild rash, oral ulcers, no organ involvement | NSAIDs + Hydroxychloroquine (HCQ) |
| Moderate | Active arthritis, serositis, significant rash, cytopenia | HCQ + low-dose prednisone (≤0.5 mg/kg/day) ± steroid-sparing DMARD |
| Severe | Major organ involvement (nephritis, CNS, vasculitis, severe hematologic) | High-dose glucocorticoids (0.5–1 mg/kg/day or pulse IV methylprednisolone) + immunosuppressive |
| Life-threatening | RPGN, diffuse alveolar hemorrhage, severe thrombocytopenia, TTP-like, severe CNS | IV pulse methylprednisolone 500–1000 mg/day × 3 days + cyclophosphamide or rituximab |
Chart 2: Drug Therapies — Dosing, Indications, Monitoring
| Drug | Dose | Indications | Key Side Effects | Monitoring |
|---|---|---|---|---|
| Hydroxychloroquine (HCQ) | ≤5 mg/kg/day (max 400 mg/day) | All SLE (baseline & maintenance); skin, joints, constitutional | Retinopathy (rare at correct dose), GI upset, rash | Annual ophthalmology after 5 yrs; CBC, LFTs |
| NSAIDs | Standard doses | Mild arthralgia, serositis, fever | GI bleed, renal toxicity, fluid retention | Renal function, BP |
| Prednisone (low dose) | ≤0.5 mg/kg/day | Moderate disease, bridge therapy | Weight gain, hypertension, glucose, osteoporosis | BMD, fasting glucose, BP |
| Prednisone (high dose) | 0.5–1 mg/kg/day (up to 60 mg/day) | Severe organ involvement | All above + infection, adrenal suppression | As above; taper as soon as possible |
| IV Methylprednisolone (pulse) | 500–1000 mg/day × 3 days | Life-threatening disease | Sudden cardiac arrhythmia, hyperglycemia, infection | Cardiac monitoring during infusion |
| Azathioprine (AZA) | 1–3 mg/kg/day | Maintenance LN (Class III/IV), skin, hematologic, pregnancy-safe IS | Myelosuppression, hepatotoxicity, nausea | CBC, LFTs monthly initially then q3mo; TPMT genotyping |
| Mycophenolate mofetil (MMF) | 2–3 g/day (induction); 1–2 g/day (maintenance) | LN Class III/IV/V, severe disease maintenance | GI upset, infection, teratogenic | CBC, renal function, LFTs |
| Cyclophosphamide (CYC) IV | NIH regimen: 0.5–1 g/m² IV monthly × 6; Euro-Lupus: 500 mg IV q2wk × 6 | Induction LN Class III/IV, severe CNS lupus, pulmonary hemorrhage | Hemorrhagic cystitis, gonadotoxicity, myelosuppression, malignancy | CBC, UA; mesna co-administration; fertility counseling |
| Methotrexate (MTX) | 7.5–20 mg/wk PO/SC | Skin, joints, serositis (refractory) | Hepatotoxicity, mucositis, teratogenic, pneumonitis | CBC, LFTs q4–8 wk; folic acid 1 mg/day; avoid in pregnancy |
| Belimumab | 10 mg/kg IV q2wk × 3, then monthly; OR 200 mg SC weekly | Active SLE despite standard therapy; LN (adjunct with MMF) | Infusion reactions, infection, depression, nausea | CBC, renal function; avoid in active CNS lupus |
| Voclosporin | 23.7 mg PO BID (with MMF) | LN Classes III, IV, V (FDA-approved 2021) | Nephrotoxicity, hypertension, infection | eGFR, BP (reduce/stop if eGFR drops >20%) |
| Anifrolumab | 300 mg IV q4 wk | Moderate-to-severe SLE, skin/joint predominant (FDA-approved 2021) | Nasopharyngitis, URTI, herpes zoster | Infection surveillance |
| Rituximab | 1000 mg IV × 2 (2 wks apart), repeat q6mo | Refractory severe SLE, AIHA, immune thrombocytopenia, refractory LN | Infusion reactions, PML (rare), severe infection, hypogammaglobulinemia | CBC, Ig levels; screen for HBV before use |
| Voclosporin + Belimumab + MMF | (see individual doses) | Lupus nephritis triple induction (FDA-approved combination) | Additive infection risk | Renal function closely |
| Dapsone | 50–150 mg/day | Skin disease (especially bullous LE, urticarial vasculitis) | Hemolysis, methemoglobinemia | G6PD screen before; CBC |
| Thalidomide | 50–300 mg/day | Refractory cutaneous LE | Teratogenicity, neuropathy, DVT | REMS program; monthly pregnancy test |
Chart 3: Lupus Nephritis — Classification & Treatment by Class
| ISN/RPS Class | Histology | Induction | Maintenance |
|---|---|---|---|
| Class I — Minimal mesangial | No immune deposits | Treat extrarenal disease; no IS for kidney | HCQ; no IS |
| Class II — Mesangial proliferative | Mesangial deposits only | Low-dose steroids if proteinuria >1 g/day | HCQ ± low-dose steroids |
| Class III — Focal proliferative | <50% glomeruli involved | High-dose steroids + MMF or CYC (Euro-Lupus preferred) | MMF 1–2 g/day or AZA |
| Class IV — Diffuse proliferative | ≥50% glomeruli | High-dose steroids + MMF or CYC; consider voclosporin add-on | MMF 1–2 g/day or AZA |
| Class V — Membranous | Subepithelial deposits; nephrotic range | Steroids + MMF (if nephrotic syndrome) | MMF preferred |
| Class VI — Advanced sclerosing | >90% sclerosis | No IS; supportive; prepare for dialysis/transplant | — |
| Mixed III+V / IV+V | Combined features | Treat as Class III/IV | MMF |
LN Induction regimens:
- NIH CYC: 0.5–1 g/m² IV monthly × 6 months
- Euro-Lupus CYC: 500 mg IV every 2 weeks × 6 doses (equivalent efficacy, less toxicity)
- MMF induction: 2–3 g/day × 6 months (preferred in non-Asian patients; comparable to CYC)
- Belimumab add-on: 10 mg/kg IV monthly added to standard-of-care (approved 2020 for LN)
Chart 4: Organ-Specific Treatment
| Organ/Manifestation | Preferred Treatment |
|---|---|
| Skin (malar/discoid rash) | Sunscreen + HCQ; topical steroids; MTX or thalidomide if refractory |
| Arthritis/arthralgia | NSAIDs + HCQ; low-dose prednisone if needed; MTX if refractory |
| Serositis (pleuritis/pericarditis) | NSAIDs or low-dose prednisone; colchicine for pericarditis |
| CNS (cerebritis, psychosis) | High-dose IV pulse steroids + CYC; anticonvulsants PRN; rituximab if refractory |
| Thrombocytopenia | High-dose steroids; IVIG (1 g/kg × 2 days) for acute severe; rituximab; splenectomy if refractory |
| AIHA | High-dose steroids; rituximab if refractory |
| Antiphospholipid syndrome (APS) | Warfarin (target INR 2–3 for venous; 3–4 for recurrent arterial); hydroxychloroquine; low-dose aspirin for prophylaxis |
| Pulmonary hemorrhage | IV pulse steroids + CYC; plasmapheresis as adjunct |
| Pulmonary hypertension | Treat underlying SLE activity + PAH-specific therapy (PDE5 inhibitors, endothelin antagonists) |
| Cardiac (myocarditis, pericarditis) | High-dose steroids; NSAIDS/colchicine for pericarditis |
| GI (mesenteric vasculitis) | High-dose steroids; CYC if severe |
Chart 5: Drug-Induced Lupus (DIL)
| Feature | DIL | Idiopathic SLE |
|---|---|---|
| Common drugs | Hydralazine, procainamide, isoniazid, minocycline, TNF inhibitors, anti-PD-1 agents | — |
| ANA pattern | Antihistone Ab (>95% DIL); anti-dsDNA rare | Anti-dsDNA, anti-Sm common |
| Renal/CNS | Rare | Common |
| Treatment | Stop offending drug; symptoms resolve in weeks–months; short-course steroids if severe | Long-term IS |
Chart 6: Pregnancy & SLE — Drug Safety
| Drug | Pregnancy Safety | Notes |
|---|---|---|
| HCQ | ✅ Safe (continue throughout) | Reduces flares in pregnancy |
| Prednisone ≤20 mg/day | ✅ Acceptable | Avoid high dose in 1st trimester |
| AZA | ✅ Acceptable (FDA Cat D but used) | Monitor CBC |
| Colchicine | ✅ Safe | For serositis/pericarditis |
| Low-dose aspirin | ✅ Safe | For APS prophylaxis |
| NSAIDs | ⚠️ Avoid after 20 wks | Premature ductus closure |
| MMF | ❌ Contraindicated | Teratogenic; switch to AZA pre-conception |
| CYC | ❌ Contraindicated | Teratogenic; only life-threatening indications |
| MTX | ❌ Contraindicated | Teratogenic; stop 3 months before conception |
| Thalidomide | ❌ Absolutely contraindicated | REMS program |
| Belimumab | ❌ Avoid | Stop 4 months before conception |
| Voclosporin | ❌ Limited data; avoid |
Chart 7: Monitoring Parameters
| Drug/Parameter | Frequency | What to Monitor |
|---|---|---|
| HCQ | Annual (after 5 yrs of use) | Ophthalmology exam (retinopathy); G6PD if deficiency suspected |
| Glucocorticoids | At initiation, then q3–6 mo | BP, fasting glucose, BMD (DEXA), lipids, ophthalmology (cataracts/glaucoma), weight |
| AZA | CBC + LFTs: q1–2 wk × 1 mo, then q1–3 mo | Myelosuppression, hepatotoxicity; TPMT genotype before starting |
| MMF | CBC + renal: monthly × 6 mo, then q3 mo | Cytopenias, infection |
| CYC | CBC before each dose; UA | Hemorrhagic cystitis (mesna), myelosuppression; cumulative dose tracking |
| MTX | CBC + LFTs q4–8 wk | Hepatotoxicity, cytopenias; folic acid 1 mg/day |
| Rituximab | Before each course: CBC, Ig levels | Hypogammaglobulinemia, HBV reactivation screen |
| Disease activity | q3 mo | SLEDAI score, complement (C3/C4), anti-dsDNA, CBC, urinalysis, creatinine |
Chart 8: Treatment Targets (Treat-to-Target)
| Target | Definition |
|---|---|
| LLDAS (Lupus Low Disease Activity State) | SLEDAI-2K ≤4, no major organ activity, no new features, PGA ≤1, prednisone ≤7.5 mg/day |
| DORIS Remission | SLEDAI-2K = 0 (clinical), PGA <0.5, prednisone ≤5 mg/day |
| Goal | Achieve LLDAS or remission; minimize steroid dose; prevent organ damage |
| LN duration of IS | Maintain IS for ≥3 years after complete renal response (KDIGO 2021) |
Sources: Harrison's Principles of Internal Medicine 22e (Ch. 368, 326, 62) — Goldman-Cecil Medicine (Ch. 245, 107) — The Washington Manual of Medical Therapeutics (Ch. 25, 15)
This is a shared conversation. Sign in to Orris to start your own chat.